Onconetix (ONCO) EBT (2021 - 2026)

Onconetix (ONCO) has reported EBT for 6 consecutive years, with -$2.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 20.86% year-over-year to -$2.9 million in Q2 2026; TTM through Jun 2026 was -$10.6 million, a 76.49% increase from a year earlier, with the FY2025 full-year figure at -$14.5 million, up 75.8% from the prior year.
• EBT was -$2.9 million for Q2 2026 at Onconetix, up from -$4.2 million in the prior quarter.
• Over five years, EBT peaked at $5.2 million in Q4 2025 and troughed at -$30.4 million in Q4 2024.
• A 5-year average of -$7.3 million and a median of -$4.3 million in 2022 frame the typical range for EBT.
• Across the five-year window, EBT slumped 588.96% in 2023 and jumped 117.29% in 2025, its largest moves.
• Over 5 years, EBT stood at -$3.2 million in 2022, then tumbled by 588.96% to -$22.4 million in 2023, then slumped by 35.74% to -$30.4 million in 2024, then soared by 117.29% to $5.2 million in 2025, then plunged by 154.64% to -$2.9 million in 2026.
• The last three EBT figures came in at -$2.9 million (Q2 2026), -$4.2 million (Q1 2026), and $5.2 million (Q4 2025), per Business Quant data.